Compare ASST & TRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASST | TRAX |
|---|---|---|
| Founded | 2020 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2022 | 2026 |
| Metric | ASST | TRAX |
|---|---|---|
| Price | $29.86 | $32.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $33.20 | ★ $70.00 |
| AVG Volume (30 Days) | ★ 7.3M | 567.8K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $633,489.00 | N/A |
| Revenue This Year | $107.15 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 128.67 | N/A |
| 52 Week Low | $0.49 | $15.69 |
| 52 Week High | $31.95 | $49.91 |
| Indicator | ASST | TRAX |
|---|---|---|
| Relative Strength Index (RSI) | 66.05 | 33.89 |
| Support Level | $10.68 | $15.69 |
| Resistance Level | $31.95 | $48.94 |
| Average True Range (ATR) | 1.57 | 2.63 |
| MACD | -0.40 | -0.56 |
| Stochastic Oscillator | 57.06 | 7.66 |
Strive Inc is a structured finance company and institutional asset manager focused on disciplined capital allocation and long term value creation. The company has adopted bitcoin as its hurdle rate for capital deployment because of its fiduciary duty to maximize long-term value for stockholders, and compounding purchasing power over time. It operates in two reportable operating segments: the Asset Management segment, which provides investment advisory services and the Corporate & Other segment, which includes the company's bitcoin treasury operations. The majority of the revenue is derived from the Asset Management segment.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.